An interventional study of Direct Ischemic Conditioning A and Direct Ischemic Conditioning B in Ischemic Stroke, sponsored by General Hospital of Shenyang Military Region. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-27.
Sponsored by General Hospital of Shenyang Military Region · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region — 16 open to participants now, 16 under way, 1 of them phase 3. Ischemic Stroke · General Hospital of Shenyang Military Region.
Among the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region, this one is the 16th largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2025, is one of 11 with no phase, reaches primary completion later than 3 of the 15 other live ones, and was the 27th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →16 of the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region are open now, in 1 country. Recruiting first, the newest first:
General Hospital of Shenyang Military Region · Sites in China
Ages 18–80
General Hospital of Shenyang Military Region · Sites in China
Ages 18–80
General Hospital of Shenyang Military Region · Sites in China
Ages 18–80
General Hospital of Shenyang Military Region · Sites in China
Ages 18+
General Hospital of Shenyang Military Region · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 5 · Phase 4 5
First in 2016; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is close to the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 145 across the 27 interventional studies, 1,000 across the 7 observational. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
General Hospital of Shenyang Military Region is the lead sponsor of 78 studies on the registry; 33 are open to participants now.
11 of the studies in Ischemic Stroke by General Hospital of Shenyang Military Region that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07135089Phase 3General Hospital of Shenyang Military RegionImproving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban | 2027-09-30 |
| NCT06170944General Hospital of Shenyang Military RegionEffect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke | 2026-11-30 |
| NCT03571763General Hospital of Shenyang Military RegionThe Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients | 2026-12-30 |
| NCT07344610General Hospital of Shenyang Military RegionEffects of Short-term Intensive Statin Therapy on Lipid Levels | 2026-12-30 |
| NCT06940128General Hospital of Shenyang Military RegionDirect Ischemic Conditioning for Endovascular Recanalization for Anterior Large Vessel Occlusion (DICER-aLVO) | 2027-01-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Acute ischemic stroke (AIS) is the most common type of stroke, with high incidence rate and mortality. Endovascular therapy is currently the most effective treatment for AIS with large vessel occlusion, but only about 50% of patients achieve good outcome after endovascular therapy, while 50% of patients have poor prognosis, commonly referred to as ineffective perfusion. Therefore, how to improve ineffective perfusion is currently a hot topic.
Numerous studies have shown that Remote Ischemic Therapy (RIC) has a protective effect on ischemic stroke. Our recent RICAMIS study has demonstrated that RIC can significantly improve the functional prognosis of moderate acute ischemic stroke. Furthermore, direct ischemic conditioning has also showed neuroprotective effect. For example, in a rat model, within 2 minutes after reperfusion, using three cycles of 30 s reperfusion and 10 s occlusion for direct ischemic conditioning can effectively alleviate hyperperfusion and reduce cerebral infarction volume. Meanwhile, in previous clinical exploration studies, it was found that even induction by 5-minute ischemia and 5-minute reperfusion for up to 4 cycles is safe, feasible, and well tolerated for AIS patients receiving endovascular treatment. Immediate control of bilateral carotid artery blood flow after ischemia-reperfusion can significantly reduce cerebral infarction area and brain edema, and improve neurological function recovery in rats. Subsequent molecular mechanism studies have shown that direct ischemic conditioning can reduce the production of free radicals after cerebral ischemia-reperfusion, inhibit inflammatory reactions and cell apoptosis, downregulate the expression of signaling molecules mediating brain edema, promote Akt survival pathway, and improve the integrity of the blood-brain barrier, thereby exerting neuroprotective effects. Recent studies have also confirmed the safety and feasibility of direct ischemic conditioning for stroke patients achieving successful recanalization. More importantly, a recent cohort study has shown that direct ischemic conditioning can reduce infarct growth and brain edema after reperfusion in patients with AIS who have undergone thrombectomy for occlusion of large blood vessels in the anterior circulation, and improve prognosis after 90 days.
Based on the above discussion, this trial aims to evaluate the effectiveness and safety of direct ischemic conditioning for patients with AIS who have undergone thrombectomy for occlusion of large blood vessels in the anterior circulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-1. Over 18 years old; 2. The time from onset to randomization is less than 24 hours; 3. Patients with acute anterior artery occlusion and receiving successful recanalization (mTICI 2b-3) after endovascular treatment and with residual stenosis ≤ 50%; 4. Cerebral circulation time after successful recanalization: affected side ≤ healthy side; 5. PH2 hemorrhage was excluded by immediate postoperative CT examination; 6. Re-onset patients with first onset or past onset without sequelae such as limb paralysis should not affect the score of this NIHSS, and mRS Score of patients with past onset should be less than 2 points; 7. Signed by patient or their legally authorized representative.
Exclusion Criteria:
- 1. Spherical enlargement of the lesion site twice or more; 2. Proximal residual stenosis >50% for patients with tandem lesions; 3. Intracranial hemorrhagic diseases: cerebral hemorrhage, subarachnoid hemorrhage, etc.
4. Chronic liver disease, liver and kidney insufficiency, elevated or AST (greater than 2 times the ), elevated serum creatinine (greater than 1.5 times the upper limit of normal) or dependent on kidney dialysis; 5. Women who are pregnant, have a pregnancy plan or are breastfeeding; 6. Combined with serious other diseases, \< 6 months; 7. Other conditions deemed inappropriate for participation in this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protocol comprised 5 cycles of 30-s balloon inflations and 30-s deflations.
Procedure: Direct Ischemic Conditioning A
The protocol comprised 4 cycles of 60-s balloon inflations and 60-s deflations.
Procedure: Direct Ischemic Conditioning B
The protocol comprised 3 cycles of 120-s balloon inflations and 120-s deflations.
Procedure: Direct Ischemic Conditioning C
Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 5 cycles of 30-s balloon inflations and 30-s deflations.
Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 4 cycles of 60-s balloon inflations and 60-s deflations.
Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 3 cycles of 120-s balloon inflations and 120-s deflations.
Proportion of patients with modified Rankin Score (mRS) 0 to 2
mRS ranges from 0-6, higher scores mean a worse outcome
Time frame: at 90±7 days
distribution of modified Rankin Score (mRS)
mRS ranges from 0-6, higher scores mean a worse outcome
Time frame: at 90±7 days
Proportion of patients with modified Rankin Score (mRS) 0 to 1
mRS ranges from 0-6, higher scores mean a worse outcome
Time frame: at 90±7 days
Proportion of early neurological improvement
early neurological improvement was defined as a 4 point or greater decrease in National Institute of Health stroke scale (NIHSS). NIHSS range from 0-42, higher scores mean a worse outcome
Time frame: at 24 (-6/+24) hours
Change in National Institute of Health stroke scale (NIHSS) score
NIHSS range from 0-42, higher scores mean a worse outcome
Time frame: at 24 (-6/+24) hours
Change in National Institute of Health stroke scale (NIHSS) score
NIHSS range from 0-42, higher scores mean a worse outcome
Time frame: at 10±2 days
The amount of contrast exudation after treatment (CT assessment)
Time frame: at 24 (-6/+24) hours
The amount of midline shift of the brain on neuroimaging after treatmet
Time frame: at 24 (-6/+24) hours
Changes in brain circulation time after treatment (between healthy side and affected side, before and after treatment of affected side ischemia)
Time frame: immediately after treatment
Recurrent stroke and new cardiovascular and cerebrovascular events
Time frame: at 90±7 days
Proportion of balloon treatment-related complications (responsible vessel re-occlusion, vagal reflex, dissection, plaque shedding, and vasospasm during and after treatment)
Time frame: immediately after treatment
Proportion of symptomatic intracranial hemorrhage
Time frame: at 24 (-6/+24) hours
Proportion of occurrence of cerebral parenchymal hemorrhage types (PH1) and (PH2)
Time frame: at 24 (-6/+24) hours
Proportion of serious adverse events
Time frame: at 24 (-6/+24) hours
Proportion of all-cause deaths
Time frame: at 10 days
Changes in serum biomarkers
Time frame: at 24 (-6/+24) hours
Changes in cerebral blood flow autoregulation ability
Time frame: at 24 (-6/+24) hours
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Jan 2027, 21 months after the start.
Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 21 months is below that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
General Hospital of Shenyang Military Region